Alyeska Investment Group
ADMS

Alyeska Investment Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Alyeska Investment Group’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-39,827
Closed -$1.03M – 550
2018
Q2 		$1.03M Buy
39,827
+1,274
+3% +$35.3K 0.01% 395
2018
Q1 		$921K Buy
+38,553
New +$1.22M 0.01% 394
2015
Q4 		– Sell
-98,380
Closed -$1.65M – 494
2015
Q3 		$1.65M Buy
98,380
+26,504
+37% +$603K 0.02% 346
2015
Q2 		$1.89M Buy
71,876
+1,163
+2% +$22.6K 0.02% 355
2015
Q1 		$1.24M Buy
70,713
+5,198
+8% +$89.1K 0.02% 417
2014
Q4 		$1.14M Buy
65,515
+43,537
+198% +$661K 0.02% 386
2014
Q3 		$409K Sell
21,978
-28,223
-56% -$486K 0.01% 363
2014
Q2 		$918K Buy
+50,201
New +$899K 0.02% 355

Other funds holding ADMS

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Alyeska Investment Group's ADMS Position: Q3 2018 in Review

Alyeska Investment Group sold out of Adamas Pharmaceuticals (ADMS) in Q3 2018, closing a stake of 39,827 shares — an estimated $1.03M sold.

Alyeska Investment Group first reported a position in ADMS in Q2 2014 and held it in 8 quarters. The position peaked at $1.89M in Q2 2015. 125 funds tracked by Wall St. Rank hold ADMS as of Q3 2018.

  • Alyeska Investment Group reported no remaining Adamas Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 39,827 Adamas Pharmaceuticals shares in Q3 2018, an estimated $1.03M.
  • Alyeska Investment Group first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 8 quarters.
  • Alyeska Investment Group's Adamas Pharmaceuticals position peaked at $1.89M in Q2 2015.
  • 125 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.